News from the FDA, Cipla and Array – People on the move
The FDA (US Food and Drug Administration) has appointed Gregory Geba as new head of the office of generic drugs.
Most recently deputy medical officer for Sanofi US, Geba replaces acting director Keith Webber
In his new role he will help to develop and enforce new generic regulations introduced as part of the User Fee Reauthorisation Bill, which passed house and senate earlier this month.
Frank Peters has been named the head of European region and global respiratory business for Indian pharma firm Cipla.
He joins the firm from Teva Pharmaceuticals, where he was senior VP of Southern Europe.
Of the new appointment, Yusuf Hamied, chairman and managing director of Cipla, said: “With him at the helm, Cipla would like to capture the huge commercial upside of 30 years experience in respiratory medicine; both in emerging and regulated markets.”
Former Hospira exec Andrew Robbins has taken the role of senior VP of commercial operations at Array BioPharma.
He will take charge of R&D (research and development) teams as well as creating new strategic collaborations.
Ron Squarer, CEO, said: “I am confident his commercial development expertise and strategic insight will contribute to Array's immediate and future successes."
Molecular Devices has named the five pharma experts who will make up its new scientific advisory board (SAB).
The members include director of the children's research institute Sean Morrison, chair of the department of chemical & systems biology at Stanford University School of Medicine Tobias Meyer, Paul Johnston, who is currently associate professor of the department of pharmaceutical sciences at the University of Pittsburgh, assistant professor in the department of chemistry at Scripps Research Institute Tobin Dickerson, and Pam Hawley-Nelson, associate director for process cell culture at MedImmune.
The team will advise on strategy, product applications and product innovation.
Former NeurAxon CEO Lawrence Bloch has become executive VP, CFO, and CBO for Infinity.
In his new position he will create finance and business development strategies for the firm, which is currently trying to integrate its operations.
“I am delighted to join Infinity, particularly at this important moment in the company’s development,” he said.
Supernus Pharmaceuticals has hired Stefan Schwabe as CMO and executive VP of R&D.
He comes to the company after serving as COO at privately held biotech, DemeRx.
“Dr. Schwabe's significant experience in CNS product development will be a major asset for us as we progress our pipeline and continue to build for future growth," said Jack Khattar, CEO, president and director.
